Phase 4 N=106 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Difference in Pain Score as Measured by a Visual Analogue Scale (VAS) — 26.4; 43.0 Units on a 100 mm VAS — p=0.0311
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=159 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds
Phase 4 N=96 Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients
Pediatrics · Anesthesia · Vasospasm
Primary: Number of Participants With Optimal Arterial Waveform — 27; 18 Participants
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
N/A N=50 Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty
Ischemia
Primary: Wound Healing — 30 Participants
Phase 3 N=134 Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Severe Hepatic Veno-Occlusive Disease
Primary: Survival at Day+100 Following Hematopoietic Stem Cell Transplant — 38.2; 25.0 percentage of participants
N/A N=35 PET/CT Imaging Companion Study To ACTG A5314
HIV · Inflammation · Atherosclerosis
Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR
N/A N=58 Exercise and Arterial Stiffness in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Arterial Stiffness — -0.26; -0.22 m/s
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
Phase 4 N=22 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Hypertension, Pulmonary · Altitude Sickness
Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg
Phase 2 N=21 Efficacy of Minoxidil in Children With Williams-Beuren Syndrome
Williams Beuren Syndrome
Primary: Variation of Carotid Intima-media Thickness (IMT) Assessed by Vascular Echography — 0.028; 0.012 mm
Phase 4 N=45 Nebivolol, Lifestyle Modification and Arterial Stiffness
Hypertension
Primary: Beta-stiffness Index — -2.03; -1.87; -2.51 Arbitrary units
Phase 3 N=366 Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
Peripheral Arterial Diseases
Primary: Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 — 21.99; 51.17 percent change — p=0.0041
N/A N=100 Technique for Successful Ultrasound-guided Peripheral Vascular Access
Obesity · Vascular Diseases
Primary: Successful First Attempt Peripheral Venous Cannulation — 96 participants
N/A N=347 Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters